Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Xuezhi Hao's publication output changed over time?
ScholarIQpublication output · 2015–2022
Output grew100% over the shown period — from 1 works in 2015 to 2 in 2022.
1
1
3
1
2
2
201520162019202020212022
What are the most-cited papers on Xuezhi Hao?
ScholarIQmost cited works
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Yuxin Mu, Xuezhi Hao, Puyuan Xing, Xingsheng Hu, Yan Wang, Li Teng, Jinyao Zhang, Ziyi Xu, Junling Li
Journal of Cancer Research and Clinical Oncology. 202067 CitationsOPEN ACCESS
miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer
Lin Lin, Haibo Lin, Lin Wang, Bin Wang, Xuezhi Hao, Yuankai Shi
S124357017. 201556 CitationsOPEN ACCESS
Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of <scp>358</scp> patients
Li‐Ling Huang, Xingsheng Hu, Yan Wang, Junling Li, Hongyu Wang, Peng Liu, Jianping Xu, Xiao‐Hui He, Xuezhi Hao, Pei‐Di Jiang, Yutao Liu, Jian Luo, Shengyu Zhou, Jin‐Wan Wang, Jian‐Liang Yang, Yan Qin, Peng Yuan, Lin Lin, Yuankai Shi
Thoracic Cancer. 202149 CitationsOPEN ACCESS
Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma
Xiaohong Han, Qiaoyun Tan, Sheng Yang, Junling Li, Jianping Xu, Xuezhi Hao, Xingsheng Hu, Puyuan Xing, Yutao Liu, Lin Lin, Lin Gui, Yan Qin, Jianliang Yang, Peng Liu, Xingyuan Wang, Wumin Dai, Dongmei Lin, Hua Lin, Yuankai Shi
Frontiers in Oncology. 201947 CitationsOPEN ACCESS
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
Yan Sun, Ying Cheng, Xuezhi Hao, Jie Wang, Chengping Hu, Baohui Han, Xiaoqing Liu, Li Zhang, Huiping Wan, Zhongjun Xia, Yunpeng Liu, Wei Li, Mei Hou, Helong Zhang, Qingyu Xiu, Yunzhong Zhu, Jifeng Feng, Shukui Qin, Xiaoyan Luo
BMC Cancer. 201645 CitationsOPEN ACCESS
Related on ScholarIQ
Chinese Academy of Medical Sciences & Peking Union Medical College
Institution
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Paper
miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer
Paper
Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of <scp>358</scp> patients
Paper
Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma
Paper
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
Paper